Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NWCI buyout rumor on the heels of key patent announcement today. "Shares could go north of $10."
Currently trading at $1.50
No brainer is ANX- Read this:
ADENTRX set to move in on GlaxoSmithKline's lucrative oncology drug
http://www.foxbusiness.com/story/markets/industries/health-care/adentrx-set-glaxosmithklines-lucrative-oncology-drug/
Fox news is raving about ANX
Here is thew link to the story:
http://www.foxbusiness.com/story/markets/industries/health-care/adentrx-set-glaxosmithklines-lucrative-oncology-drug/
Now it's obvious what the Street thinks- calls CTIC worst of the worst---
http://www.thestreet.com/story/10509090/1/top-takes-from-realmoney.html?cm_ven=GOOGLEFI
By Adam Feuerstein
Cell Therapeutics(CTIC Quote), Hemispherx Biopharma(HEB Quote), Antigenics(AGEN Quote) and Oculus Innovative Sciences(OCLS Quote) are all flying higher in a whirlwind of speculative, retail and daytrading activity. All these companies have experimental drugs and/or products that are among the worst of the worst. Yet the stocks are extremely hard or expensive to borrow, and that is putting short-sellers in a bind.
Hope you're right my friend. Very good observations.
What is THAT about? Dillution? MM games? WTF?
Okay, but what does it mean? It's a debt swap no?
Here is the real news today:
http://www.officialwire.com/main.php?action=posted_news&rid=4678&catid=18
Significant cancer news for CTIC- up 11%
already traded almost 8 million shares--
http://www.officialwire.com/main.php?action=posted_news&rid=4678&catid=18
CTIC is going nuts with 4 million+ volume in pre-market
News is out:
http://www.officialwire.com/main.php?action=posted_news&rid=4678&catid=18
That's huge volume in the pre-market!
News is out!!!
http://www.tradingmarkets.com/.site/news/Stock%20News/2358071/
What do you make of that PR? Lots of "CTIC looking at takeover" rumors on yahoo and google boards. What's the story?
This is the second time a publicly traded biotech has slapped Adam. In case you missed it.
While I don't believe you need to have a degree in computer science to report on the computer industry, for example. I do think you need to be a real journalist and dig for the facts- not just speculate and cause stocks to drop in price to the tune of millions without repercussions.
Then again. Is he to blame or all the sheeple who use him for their stock advice?
What a joke!
Link?
No hard feelings, mate.
Thanks. I dunno that it's a great investment, but it made for a great trade. Wonder how it will do today?
"Pink Bio May Move Markets With Cancer Vaccine News"
http://biomedreports.com/articles/most-popular/1099-pink-bio-play-may-move-markets-with-cancer-vaccine.html
No problem. This is the biotech play everyone is holding on to in hopes that it's going to pay better than DNDN and pther recent ones.
It's imprtant to note that the HEB insiders are VERY confident that Ampligen will be approved. Especially given the wording in the last PR about why they went out to raise more capital:
http://sev.prnewswire.com/health-care-hospitals/20090527/NY2255827052009-1.html
These financings were conducted to generate additional capital to fund the final development and introduction of Ampligen, for Chronic Fatigue Syndrome, in the US market. Wayne Pambianchi, Executive Director of The Sage Group, said, "HemispherX's success in closing this important financing in this troubled financial market, is a clear reflection of the perceived importance of their Ampligen technology in a broad range of immunological applications."
Actually, they often approve a day or two before the due date. GTCB was a recent example of that.
The new HEB report everyone is quoting just got updated this morning and it now has even more info including a quote from Dr. Carter himself.
LINK:
http://biomedreports.com/articles/most-popular/1032-us-govt-takes-additional-steps-toward-development-of-takes-additional-steps-toward-development-of-vaccine-for-the-novel-influenza-a-h1n1.html
The new HEB report everyone is quoting just got updated this morning and it now has even more info including a quote from Dr. Carter himself.
LINK:
http://biomedreports.com/articles/most-popular/1032-us-govt-takes-additional-steps-toward-development-of-takes-additional-steps-toward-development-of-vaccine-for-the-novel-influenza-a-h1n1.html
VNBCO preferred is up 400% today. Any idea why?
Cell Therapeutics: Turnaround Remains On Track
http://biomedreports.com/articles/most-popular/924-cell-therapeutics-turnaround-remains-on-track.html
Written by Mike Havrilla - BiomedReports.Com
Thursday, 07 May 2009 14:56
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.
CTIC achivied its objective thus far during 1H09, including the initiation of the rolling NDA submission for pixantrone, reducing net loss through cost cutting initiatives, raising gross proceeds of $44.3M, and cleaning up the Company's capital structure through the elimination of all previously issued preferred stock. CTIC is on target to complete the pixantrone NDA filing by June and if the FDA grants a priority revew, the Company could receive an approval decision before year-end in December.
The Company riased $23.8M through the sale of newly-issued preferred stock to a single institutional investor and the exercise of common stock warrants associated with the transaction. All shares of preferred stock in the deal were subsequently converted into common stock by the investor so that CTIC has no preferred stock outstanding at this time. CTIC received $20.5M in gross proceeds earlier this year from Spectrum Pharma (SPPI) as part of the sale of its 50% stake in their previous joint venture to market cancer drug Zevalin.
CTIC reduced its total net operating expenses by $21.8M to $6.6M for 1Q09, compared to $28.4M in the year-ago period due to the $10.2M one-time gain on the Zevalin joint venture sale along with a decline in R&D spending (down by 50% to $8M versus the year-ago period). Exlcuding the one-time gain, operating expenses still decreased by 41% from the year-ago period. The net loss attributable to common shareholders decreased by 76% or $41.5M to $13.1M or ($0.05) per share, compared to $54.6M or ($7.68) per share in the year-ago period.
Below are links to my previous articles on CTIC at BioMedReports.com:
1.) Cell Therapeutics: Down, but Not Out - 2/20/09
http://biomedreports.com/bloglist/542.html
2.) A Resurgence in Cell Therapeutics - 4/2/09
http://biomedreports.com/articles/most-popular/752-a-resurgence-in-cell-therapeutics.html
3.) FDA, Clinical Trial Calendar Updates - 4/21/09
http://biomedreports.com/articles/most-popular/839-fda-clinical-trial-calendar-updates-ctic-cypb-frx-mrk.html
4.) FDA Calendar Updates - 5/5/09
http://biomedreports.com/articles/most-popular/902-fda-calendar-updates-ctic-alks-amln-lly.html
Cell Therapeutics: Turnaround Remains On Track
http://biomedreports.com/articles/most-popular/924-cell-therapeutics-turnaround-remains-on-track.html
Written by Mike Havrilla - BiomedReports.Com
Thursday, 07 May 2009 14:56
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.
CTIC achivied its objective thus far during 1H09, including the initiation of the rolling NDA submission for pixantrone, reducing net loss through cost cutting initiatives, raising gross proceeds of $44.3M, and cleaning up the Company's capital structure through the elimination of all previously issued preferred stock. CTIC is on target to complete the pixantrone NDA filing by June and if the FDA grants a priority revew, the Company could receive an approval decision before year-end in December.
The Company riased $23.8M through the sale of newly-issued preferred stock to a single institutional investor and the exercise of common stock warrants associated with the transaction. All shares of preferred stock in the deal were subsequently converted into common stock by the investor so that CTIC has no preferred stock outstanding at this time. CTIC received $20.5M in gross proceeds earlier this year from Spectrum Pharma (SPPI) as part of the sale of its 50% stake in their previous joint venture to market cancer drug Zevalin.
CTIC reduced its total net operating expenses by $21.8M to $6.6M for 1Q09, compared to $28.4M in the year-ago period due to the $10.2M one-time gain on the Zevalin joint venture sale along with a decline in R&D spending (down by 50% to $8M versus the year-ago period). Exlcuding the one-time gain, operating expenses still decreased by 41% from the year-ago period. The net loss attributable to common shareholders decreased by 76% or $41.5M to $13.1M or ($0.05) per share, compared to $54.6M or ($7.68) per share in the year-ago period.
Below are links to my previous articles on CTIC at BioMedReports.com:
1.) Cell Therapeutics: Down, but Not Out - 2/20/09
http://biomedreports.com/bloglist/542.html
2.) A Resurgence in Cell Therapeutics - 4/2/09
http://biomedreports.com/articles/most-popular/752-a-resurgence-in-cell-therapeutics.html
3.) FDA, Clinical Trial Calendar Updates - 4/21/09
http://biomedreports.com/articles/most-popular/839-fda-clinical-trial-calendar-updates-ctic-cypb-frx-mrk.html
4.) FDA Calendar Updates - 5/5/09
http://biomedreports.com/articles/most-popular/902-fda-calendar-updates-ctic-alks-amln-lly.html
Guys--- What about this Vinyard News??
Vineyard National Bancorp Receives Notice From NASDAQ and NYSE Amex LLC Confirming Delisting
9:01a ET April 22, 2009 (Market Wire)
Vineyard National Bancorp (NASDAQ: VNBC) (NYSE Amex: VXC.PR.D) (the "Company") announced today that on April 16, 2009, the Company received a NASDAQ Staff Determination letter notifying the Company that its failure to pay its annual listing fee constitutes a failure to satisfy the filing requirement for continued listing under NASDAQ Marketplace Rule 5210(d) and, therefore, trading in the Company's common stock will be suspended at the opening of business on April 27, 2009 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC") which will remove the Company's common stock from listing and registration on The NASDAQ Stock Market. The letter from NASDAQ advised us that the Company's common stock will not be immediately eligible to trade on the OTC Bulletin Board or in the "Pink Sheets."
On April 17, 2009, the Company also received correspondence from NYSE Amex LLC advising the Company that because the Company did not file an appeal regarding the delisting notice received on April 9, 2009, trading in the Company's 7.5% Series D Noncumulative Preferred Stock ("Preferred Stock") will be suspended at the opening of business on April 22, 2009. The correspondence from NYSE Amex advised us that the Company's Preferred Stock will automatically default to the Pink Sheets and be designated a new ticker.
About Vineyard National Bancorp
The Company is a $2.0 billion financial holding company headquartered in Corona, and the parent company of Vineyard Bank, N.A. ("Vineyard"). Vineyard, also headquartered in Corona, operates through 16 full-service banking centers and one regional financial center in the counties of Los Angeles, Marin, Orange, Riverside, San Bernardino, San Diego, and Ventura, Calif. The Company's common stock is traded on the NASDAQ Global Select Market under the symbol "VNBC." For additional information on the Company visit www.vnbcstock.com or for additional information on Vineyard and to access internet banking, please visit www.vineyardbank.com.
Forward-Looking Statements
Certain matters discussed herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the Company and the statements contained herein can be found in the Company's filings with the SEC including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements herein, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and other protections under the Federal securities laws. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=965471 Contact: Shareholder Relations 951-271-4232 shareholderinfo@vineyardbank.com
SOURCE: Vineyard National Bancorp
BiomedReports: FDA Calendar Updates for Amylin Pharma, Cell Therapeutics, Eli Lilly and Alkermes
http://www.tradingmarkets.com/.site/news/Stock%20News/2310640/
There are new updates to BioMedReports.com's database of FDA and Clinical Trial Calendars (NASDAQ:AMLN) (NASDAQ:ALKS) (NYSE:LLY) (NASDAQ:CTIC).
Amylin Pharma (NASDAQ:AMLN), Eli Lilly (NYSE:LLY), and Alkermes (NASDAQ:ALKS) announced today that a NDA was filed for FDA approval of a once-weekly version of exenatide (Byetta LAR) as once weekly formulation for type 2 diabetes which is administered by subcutaneous injection.
Cell Therapeutics (NASDAQ:CTIC) announced today that pixantrone is available on a named-patient basis for use in Europe to treat patients with aggressive non-Hodgkin's lymphoma that has either relapsed or is refractory to standard treatment options.
A full report on the developments and how they affect upcoming FDA decisions and approvals is available on the BiomedReport's FDA Calendar, which includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
FDA Calendar Access: http://biomedreports.com/component/content/article/548.html
BiomedReports: FDA Calendar Updates for Amylin Pharma, Cell Therapeutics, Eli Lilly and Alkermes
http://www.tradingmarkets.com/.site/news/Stock%20News/2310640/
There are new updates to BioMedReports.com's database of FDA and Clinical Trial Calendars (NASDAQ:AMLN) (NASDAQ:ALKS) (NYSE:LLY) (NASDAQ:CTIC).
Amylin Pharma (NASDAQ:AMLN), Eli Lilly (NYSE:LLY), and Alkermes (NASDAQ:ALKS) announced today that a NDA was filed for FDA approval of a once-weekly version of exenatide (Byetta LAR) as once weekly formulation for type 2 diabetes which is administered by subcutaneous injection.
Cell Therapeutics (NASDAQ:CTIC) announced today that pixantrone is available on a named-patient basis for use in Europe to treat patients with aggressive non-Hodgkin's lymphoma that has either relapsed or is refractory to standard treatment options.
A full report on the developments and how they affect upcoming FDA decisions and approvals is available on the BiomedReport's FDA Calendar, which includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
FDA Calendar Access: http://biomedreports.com/component/content/article/548.html
Reversal of Fortune for Two Biomed Rivals
LOS ANGELES - May 01, 2009 - Sequenom Inc. (NASDAQ:SQNM) topped the list of biggest percentage price decliners among common stocks
on the Nasdaq Stock Market on Thursday.
Meanwhile, EXACT Sciences (NASDAQ:EXAS) is poised to continue its comeback from penny stock
levels late last year and has a chance to close the year at a higher market value than its molecular
diagnostics rival.
BiomedReports.Com reports on the interesting reversal of fortune for these two rivals whose ties run deep.
Months ago, Sequenom launched a hostile, all-stock tender offer for EXACT Sciences earlier this year for $1.50 per share (which would now be valued at less than 40 cents), but EXACT rejected the deal in favor of a strategic pact with Genzyme (NASDAQ:GENZ) which involved a $24.5M cash infusion.
SQNM was trading around 25 bucks in late January, but published news reports indicate that Sequenom publicized clinical data throughout 2008 and 2009, which it claimed confirmed the strong efficacy of Sequenom's prenatal genetic test for Down syndrome.
On April 29, 2009, Sequenom disclosed "employee mishandling" of the clinical data, which raised "significant concerns regarding the integrity of that data."
In the first hour of trading on Thursday, Sequenom shares plunged 77%, or $11.43, to $3.48 on 27 times its average daily volume over the past 30 days.
A full special report on the companies appears today at:
http://biomedreports.com/articles/most-popular/885-sequenom-splattered-exact-sciences-on-the-rise.html
Reversal of Fortune for Two Biomed Rivals
LOS ANGELES - May 01, 2009 - Sequenom Inc. (NASDAQ:SQNM) topped the list of biggest percentage price decliners among common stocks
on the Nasdaq Stock Market on Thursday.
Meanwhile, EXACT Sciences (NASDAQ:EXAS) is poised to continue its comeback from penny stock
levels late last year and has a chance to close the year at a higher market value than its molecular
diagnostics rival.
BiomedReports.Com reports on the interesting reversal of fortune for these two rivals whose ties run deep.
Months ago, Sequenom launched a hostile, all-stock tender offer for EXACT Sciences earlier this year for $1.50 per share (which would now be valued at less than 40 cents), but EXACT rejected the deal in favor of a strategic pact with Genzyme (NASDAQ:GENZ) which involved a $24.5M cash infusion.
SQNM was trading around 25 bucks in late January, but published news reports indicate that Sequenom publicized clinical data throughout 2008 and 2009, which it claimed confirmed the strong efficacy of Sequenom's prenatal genetic test for Down syndrome.
On April 29, 2009, Sequenom disclosed "employee mishandling" of the clinical data, which raised "significant concerns regarding the integrity of that data."
In the first hour of trading on Thursday, Sequenom shares plunged 77%, or $11.43, to $3.48 on 27 times its average daily volume over the past 30 days.
A full special report on the companies appears today at:
http://biomedreports.com/articles/most-popular/885-sequenom-splattered-exact-sciences-on-the-rise.html
HEB News-- Skyrocketing as I type this
http://www.globenewswire.com/newsroom/news.html?d=163911
Japanese Government Accelerates Hemispherx Biopharma's Ampligen(r) Research Programs for Influenza Protection
Flu Virus Mutations May Limit Tamiflu Usefulness
HEB News-- Skyrocketing as I type this
http://www.globenewswire.com/newsroom/news.html?d=163911
Japanese Government Accelerates Hemispherx Biopharma's Ampligen(r) Research Programs for Influenza Protection
Flu Virus Mutations May Limit Tamiflu Usefulness
HEB exploding on news of the swine Flu
Not only that, but it has an FDA approval coming next month.
BOSTON (MarketWatch) -- Shares of niche makers of antiviral products and vaccines saw shares rocket in early trading Monday on news that the world could be facing a global pandemic of the swine flu virus.
Concerns about the growing health crisis helped boost drug stocks into positive territory while the broader market slid into the red. The Amex Pharmaceutical Index (DRG ) rose 1.2% to 236.04 and the Amex Biotechnology Index (BTK ) jumped 1.5% to 626.90. Meanwhile, the Dow Jones Industrial Average slid about 65 points, or 0.8%, to 8,009.
Leading the pack was Biota Holdings Ltd. (BTAHY, Trade )(BTAHF, Trade ), with U.S.-traded shares shooting up over 600% to $4.40. Australia-based Biota receives royalties on a leading flu-fighting agent, Relenza, which is marketed by GlaxoSmithKline PLC. (GSK, Trade )
Also gaining at least 50% were Generex Biotechnology Corp. (GNBT, Trade ), BioCryst Pharmaceuticals (BCRX, Trade ), Novavax Inc. (NVAX, Trade ) and Hemispherx Biopharma Inc (HEB, Trade ). Advancing at least 15% were shares of Vical Inc. (VICL, Trade ) and Peregrine Pharmaceuticals. (PPHM, Trade )
Many of the companies have also been active in developing products to combat a deadly strain of the avian flu called H5N1, which has been eyed over the years by world health officials as a pandemic threat. The current swine flu virus is of a strain called H1N1.
Large-scale anti-viral developers Gilead Sciences (GILD, Trade ), Roche Holding (RHHBY, Trade ) and GlaxoSmithKline PLC were also up significantly.
Gilead developed a leading flu-fighter, Tamiflu, also called oseltamivir. The biotech group receives royalties on Tamiflu sales from marketer Roche (RHHBY, Trade ).
Shares of Gilead were up 3% at $47.03, as shares of Roche climbed 4% to $31.54. Shares of Glaxo were up 6% at $31.03.
Gilead reported last week that it took in $33 million in Tamiflu royalties, down from $93 million the previous year. Gilead attributed the drop to stockpiling by health agencies worldwide in preparation of a possible pandemic of the avian flu virus.
According to Biota's website, Relenza had sales of $462 million for the quarter ended March 31, garnering the company about $32 million in royalties. Biota noted that the U.K. and British governments had recently ordered "significant" amounts of the product as part of their pandemic stockpiling measures.
Lazard Capital Markets analyst Joel Sendek said in a note early Monday that the Centers for Disease Control suspects other flu-fighting agents are ineffective against the swine flu virus and is recommending either oseltamivir or zanamivir to treat patients.
"Gilead is likely a beneficiary of the current situation. We anticipate increased retail sales of Tamiflu as people with suspicious symptoms consistent with the flu are likely to purchase Tamiflu. We also expect additional government stockpiling in the future given the scale and speed of the current swine flu emergency," wrote Sendek, who tracks Gilead.
Trading amongst the remaining major vaccine makers was more mixed. As opposed to other pharmaceutical products, flu vaccines require months of production.
Shares of Baxter International (BAX, Trade ) rose 3% to $49.33, while AstraZeneca PLC (AZN, Trade ) shares were up 5% at $36.36. Shares of Sanofi-Aventis (SNY, Trade ) edged up 2% to $27.27.
Novartis AG (NVS, Trade ) was the only large-scale vaccine maker trading in the red, with shares down almost 1% at $36.66.
HEB exploding on news of the swine Flu
Not only that, but it has an FDA approval coming next month.
BOSTON (MarketWatch) -- Shares of niche makers of antiviral products and vaccines saw shares rocket in early trading Monday on news that the world could be facing a global pandemic of the swine flu virus.
Concerns about the growing health crisis helped boost drug stocks into positive territory while the broader market slid into the red. The Amex Pharmaceutical Index (DRG ) rose 1.2% to 236.04 and the Amex Biotechnology Index (BTK ) jumped 1.5% to 626.90. Meanwhile, the Dow Jones Industrial Average slid about 65 points, or 0.8%, to 8,009.
Leading the pack was Biota Holdings Ltd. (BTAHY, Trade )(BTAHF, Trade ), with U.S.-traded shares shooting up over 600% to $4.40. Australia-based Biota receives royalties on a leading flu-fighting agent, Relenza, which is marketed by GlaxoSmithKline PLC. (GSK, Trade )
Also gaining at least 50% were Generex Biotechnology Corp. (GNBT, Trade ), BioCryst Pharmaceuticals (BCRX, Trade ), Novavax Inc. (NVAX, Trade ) and Hemispherx Biopharma Inc (HEB, Trade ). Advancing at least 15% were shares of Vical Inc. (VICL, Trade ) and Peregrine Pharmaceuticals. (PPHM, Trade )
Many of the companies have also been active in developing products to combat a deadly strain of the avian flu called H5N1, which has been eyed over the years by world health officials as a pandemic threat. The current swine flu virus is of a strain called H1N1.
Large-scale anti-viral developers Gilead Sciences (GILD, Trade ), Roche Holding (RHHBY, Trade ) and GlaxoSmithKline PLC were also up significantly.
Gilead developed a leading flu-fighter, Tamiflu, also called oseltamivir. The biotech group receives royalties on Tamiflu sales from marketer Roche (RHHBY, Trade ).
Shares of Gilead were up 3% at $47.03, as shares of Roche climbed 4% to $31.54. Shares of Glaxo were up 6% at $31.03.
Gilead reported last week that it took in $33 million in Tamiflu royalties, down from $93 million the previous year. Gilead attributed the drop to stockpiling by health agencies worldwide in preparation of a possible pandemic of the avian flu virus.
According to Biota's website, Relenza had sales of $462 million for the quarter ended March 31, garnering the company about $32 million in royalties. Biota noted that the U.K. and British governments had recently ordered "significant" amounts of the product as part of their pandemic stockpiling measures.
Lazard Capital Markets analyst Joel Sendek said in a note early Monday that the Centers for Disease Control suspects other flu-fighting agents are ineffective against the swine flu virus and is recommending either oseltamivir or zanamivir to treat patients.
"Gilead is likely a beneficiary of the current situation. We anticipate increased retail sales of Tamiflu as people with suspicious symptoms consistent with the flu are likely to purchase Tamiflu. We also expect additional government stockpiling in the future given the scale and speed of the current swine flu emergency," wrote Sendek, who tracks Gilead.
Trading amongst the remaining major vaccine makers was more mixed. As opposed to other pharmaceutical products, flu vaccines require months of production.
Shares of Baxter International (BAX, Trade ) rose 3% to $49.33, while AstraZeneca PLC (AZN, Trade ) shares were up 5% at $36.36. Shares of Sanofi-Aventis (SNY, Trade ) edged up 2% to $27.27.
Novartis AG (NVS, Trade ) was the only large-scale vaccine maker trading in the red, with shares down almost 1% at $36.66.
Chrysler Reaches Labor Accord With U.S. Union, CAW Ratification
April 27 (Bloomberg) -- Chrysler LLC, racing against an April 30 deadline to cut labor costs or face bankruptcy, reached a tentative contract agreement with its biggest U.S. union and won ratification of an accord with Canadian workers.
Members of the United Auto Workers must still vote on their proposed money-saving contract, according to a statement yesterday from the Detroit-based union. Employees represented by the Canadian Auto Workers approved a contract that may save the automaker C$240 million ($197 million) annually.
The moves boost Chrysler’s attempt to avoid a government- ordered bankruptcy. Union workers must accept less-generous contracts so Chrysler can form an alliance with Italy’s Fiat SpA and qualify for more U.S. and Canadian aid. The company still must get lenders to erase most of $6.9 billion in secured debts.
“The chances of them pulling this off are much better now,” said Erich Merkle, an independent auto analyst in Grand Rapids, Michigan. “I wouldn’t say they are completely out of the woods yet.”
Chrysler received a $4 billion loan from the government in early January and has been told it will get $500 million more. It may get as much as $6 billion in additional loans by completing a Fiat alliance before the April 30 deadline.
“Chrysler continues to focus on reaching the deadlines set by the U.S. and Canadian governments,” said Shawn Morgan, a company spokeswoman, in an interview. “The announcements this weekend are important steps toward reaching these objectives.”
Health-Care Fund
The new UAW contract must be ratified by Auburn Hills, Michigan-based Chrysler’s 26,800 U.S. workers represented by the union.
“The patience, resolve and determination of UAW members in these difficult times is extraordinary, and has made it possible for us to reach the agreement we will present to our membership,” said UAW President Ron Gettelfinger in the statement.
The UAW’s health-care trust fund for retirees will take about 20 percent ownership in Chrysler after the automaker’s restructuring in exchange for lowering the company’s obligation to contribute cash to the $10.6 billion fund, people familiar with the negotiations have said.
Benefit Concessions
“We commend the UAW’s leadership for their endless determination and perseverance in reaching this tentative agreement, especially during these unprecedented economic circumstances that plague the automotive industry,” said Al Iacobelli, lead negotiator for Chrysler, in a statement.
The CAW, representing about 8,000 Chrysler workers in Ontario, said in a statement yesterday that 87 percent of votes cast were in favor of ratifying the accord.
CAW leaders reached an agreement with Chrysler on April 24 after two months of on-and-off talks. The members will give up benefits including tuition rebates and a car-buying program. Base wages and pensions do not change.
Fiat Chief Executive Officer Sergio Marchionne had said he wouldn’t form the Chrysler alliance without the new CAW savings. Cerberus Capital Management LP owns 80.1 percent of Chrysler, while former parent Daimler AG owns the rest.
Chrysler’s Canadian union deal is no guarantee that the company will stay out of bankruptcy, Lewenza said April 24.
The CAW was told by Chrysler that in the event of a bankruptcy, the company would be “split in half: The new company and the old company,” Lewenza said. “And the old company would be liquidated.”
Shift Eliminated
The CAW’s Canadian operations would be placed in the new company should Chrysler file for bankruptcy court protection, Lewenza said.
Chrysler will cut the third shift at the company’s factory in Windsor, Ontario, CAW officials said. They plan to pursue Fiat work for the assembly plant, which makes Dodge Grand Caravan and Chrysler Town & Country minivans.
The CAW said its agreement includes more cost-saving provisions than a contract negotiated with General Motors Corp., which is also trying to restructure out of court. Additional concessions include the elimination of semi-private hospital coverage and of a one-time C$3,500 vacation buyout negotiated last year.
The CAW will now begin bargaining with GM and Ford Motor Co. on similar agreements in Canada, Lewenza said.
GM had said that its contract, ratified last month, would cut total labor costs below those of U.S. operations of foreign automakers such as Toyota Motor Corp.
Chrysler and the Canadian and Ontario governments had demanded C$19 an hour in cuts in benefits and other concessions to reduce hourly labor costs to C$57. The C$240 million in annual savings over 12.5 million hours worked meets that benchmark, the union said.
The CAW and Chrysler agreed to establish a retiree health- care trust, similar to those negotiated by the UAW, which represents hourly workers at the company’s U.S. factories.
GM to announce brand changes, restructuring moves
41 minutes ago
DETROIT (AP) — General Motors will announce a restructuring plan at 9 a.m. EDT today. The storied Pontiac brand is dead and more car factories and jobs are about to disappear — the latest casualties of a plan that GM is counting on to help it stave off bankruptcy protection. The plan is being announced as GM makes an offer to its bondholders to swap debt for company stock. GM owes $28 billion to large and small bondholders, and under Securities and Exchange Commission rules, it must disclose its operational plans when it makes an exchange offer.
Two people briefed on GM's plan confirmed that it includes the demise of Trans Am sports car brand Pontiac, 83 years after the first Pontiac car was introduced. Within three years, half a million Pontiacs were sold, and the brand quickly grew in popularity, from early models like the Chief and the Master Six Coupe, to the Bonneville convertible, to the GTO — one of America's first muscle cars and so popular it inspired Ronny and the Daytonas to immortalize it in song.
But efforts in the last few years to market Pontiac as performance-oriented brand failed. The company had said it wanted to keep Pontiac as a niche brand with one or two models, but is buckling under tremendous government pressure to consolidate its eight brands, several of which lose money.
The company also has decided to close more factories than the five it announced in February, the two people said, asking not to be identified because the plan has not yet been made public. But the locations of the doomed factories will not be identified Monday.
One of the people said GM will list specific numbers of blue-collar job cuts, and announce another round of U.S. salaried job cuts beyond the 3,400 completed last week.
Chief Executive Fritz Henderson has said the company will go further and faster in making its cost cuts to reduce the number of cars and trucks it needs to sell to break even. One of the people briefed on the plan said GM will accelerate many cuts previously planned for 2014 to instead take place between now and 2010, although specifics were not available.
The people said GM won't have much new information on Hummer, Saturn or other brands, including Europe's Opel. GM has indicated it wants to focus on four core brands, Chevrolet, Cadillac, GMC and Buick.
Also to be announced Monday will be a target number for dealer reduction, as well as details of GM's bond exchange offer. Exact numbers were not available Sunday night.
The news conference will include Chief Executive Fritz Henderson, Chief Financial Officer Ray Young, North American President Troy Clarke and Mark LaNeve, vice president of North American sales and marketing.
GM is living on $15.4 billion in government loans and faces a government-imposed June 1 deadline to restructure or go into bankruptcy protection.
The government's restructuring demands include swapping at least two thirds of GM's unsecured bond debt for equity in the company. Such a move would help GM straighten out its debt-laden balance sheet.
Chrysler LLC, which is living on $4 billion in government loans and is expected to get $500 million more, faces a Thursday deadline to restructure and ink an alliance deal with Italian automaker Fiat SpA. The government also wants Chrysler to exchange much of its $6.9 billion in debt for equity in the company, but with the deadline fast approaching, Chrysler and its secured debtholders remain far apart.
Both GM and Chrysler also must win concessions from the United Auto Workers union.
The UAW said late Sunday it reached agreement on concessions with Chrysler, Fiat and the U.S. government. Fiat CEO Sergio Marchionne was in the U.S. as talks continued for the automaker to take a 20 percent stake in Chrysler in exchange for its small-car technology.
http://www.google.com/hostednews/ap/article/ALeqM5jRROQxrU3YC0QnDQpk9h_BC6pZ5wD97QPBP81
GM Strains to Sustain Its Marketing in Maelstrom
DETROIT (AdAge.com) -- Marketing at General Motors Corp. is starting to resemble stuffing towels into the bow of the Titanic.
Last week the troubled automaker reduced its marketing and communications staff 20% -- an estimated 60 to 80 people -- as part of a wider 1,600-person reduction, and Automotive News is reporting that GM will announce this week that it's going to close Pontiac. Another brand slated for disposal, Saturn, is spending what appears to be millions on regional ads themed "We're still here," yet sales for the brand sunk 62% in the first quarter, and it seems unlikely consumers are putting too much store by Saturn's reassurances, given that everyone is anticipating the marque's demise.
According to GM, its similarly consumer-soothing "Total Confidence" campaign, which protects consumers for up to nine car payments up to $500 monthly in case of job loss, has raised traffic to dealerships. But so far, it hasn't converted that traffic into sales.
On top of all that, while GM intends to participate in the network TV upfront next month, when marketers reserve ad time for the upcoming season, it may be forced to do so on a "cash-only" basis.
The government is requiring GM to reach acceptable agreements with creditors by June 1 in order to avoid bankruptcy, and that deadline is fast approaching. It's also far from fortuitous for the media world, given that it occurs a month after the TV upfront. GM spent some $2 billion in total measured media last year, and media sellers worry that the marketer -- not to mention Chrysler, which spent $700 million last year -- won't be able to pay for time it corrals in the upfront.
'Cash-only upfront'
According to one media-buying executive, there are discussions about forcing GM and Chrysler into a "cash-only upfront," standard practice in the event of a bankruptcy. In other words, while most participants in the upfront simply make commitments to spend money and approve their orders much later, a bankrupt marketer would have to pay for the time it wants to secure in the fall with cash on the table.
An executive familiar with both sides of the issue said the TV networks should be "very concerned" about doing upfront deals with GM, since there is a risk they would be unsecured creditors in a bankruptcy. But the networks would have time to resell the spots to other advertisers, the executive said. They should be more concerned about scatter, or ad time bought close to a show's air date, since they would be less likely to get paid for that and have less time to resell it should GM enter Chapter 11 proceedings.
Chrysler, meanwhile, might be forced to file for bankruptcy as soon as this week, yet it is continuing to toil on a new campaign slated to break next month. While the automaker has been trying to finalize a deal with Italian automaker Fiat, and the ads under way are not contingent on a deal, according to an executive familiar with the matter. The plan is to focus on Dodge, Chrysler and Jeep products coupled with a corporate message, changing the copy or narration depending on which of the automaker's two scenarios unfolds. Chrysler's shop, Omnicom Group's BBDO, Detroit and New York, referred calls for comment to Chrysler, which declined to comment.
A Chrysler dealer termed the company's current situation "a little bit frightening," since executives aren't communicating very well with the automaker's roughly 3,000 retailers, whose livelihoods are at stake. A second dealer said stoking demand won't help much, because auto buyers still can't get credit.
Traffic, not sales
GM's "Total Confidence" program is building dealer traffic, if not sales. Michael Maroone, president of AutoNation, the country's biggest dealership chain, said the program "is allowing GM to hold its own in a very difficult market," though he acknowledged, "Traffic is better than sales."
A company spokeswoman said the ads, from GM's corporate agency, Interpublic Group of Cos.' McCann Erickson, Birmingham, Mich., have generated increased traffic to both showrooms and GM websites, and the company expects its new-vehicle sales to be better in April than they were in March.
Despite all the negative news, GM research found that consumer opinion and consideration for its Chevrolet and GMC vehicle brands increased in the past six months through March, according to the company. Mike DiGiovanni, GM's director-industry analysis, said recently that Americans' consideration for the corporate GM brand is "way down," but "when you look at Chevrolet, Cadillac and our other brands, they haven't changed." He added, "It's hard to believe."
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
There are updates for those companies in the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.
http://biomedreports.com/articles/most-popular/843-fda-clinical-trial-calendar-updates-genzyme-isis-osiris-roche-watson.html
FDA, Clinical Trial Calendar Updates: Genzyme (NASDAQ:GENZ), Isis (NASDAQ:ISIS), Osiris (NASDAQ:OSIR), Roche(RHHBY.PK), Watson
(NYSE:WPI)
There are updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.
http://biomedreports.com/articles/most-popular/843-fda-clinical-trial-calendar-updates-genzyme-isis-osiris-roche-watson.html
New board dealing with the Six Flags Perf stock:
http://investorshub.advfn.com/boards/board.aspx?board_id=15158
Agreed!
Here are some other movers:
http://biomedreports.com/articles/most-popular/817-fda-calendar-stocks-on-the-move-dsco-vion-nfld.html